Avalo Therapeutics, Inc. (AVTX) Cash Flow Statement

The gap between net income and operating cash flow is extreme, with quarters like Q2 2024 showing a $98.5M gain but only -$16.3M in operating cash flow, indicating that reported earnings are heavily influenced by non-cash items such as warrant revaluations. Conversely, Q1 2024's -$121.3M loss was accompanied by a modest -$6.2M operating cash outflow, suggesting that the loss was largely non-cash. This volatility makes net income a poor proxy for underlying cash generation, and investors should focus on cash burn as the more reliable indicator of financial health.

The quarterly FCF deficit has more than tripled over the period, reflecting escalating R&D costs as the lead asset advances toward registrational trials. The positive Phase 2 LOTUS results have de-risked the pipeline but also signaled the start of a more capital-intensive phase, with no revenue to offset the burn. Given the $15.8M cash position, the current burn rate implies a runway of less than one quarter unless additional capital is secured, making near-term dilution or partnership deals highly likely.

The absence of CapEx is typical for a clinical-stage biotech that outsources manufacturing and relies on CROs, but it also means that the entire cash burn is directed toward intangible asset development. This structure provides flexibility but also means that the company has no tangible asset base to collateralize or sell in a distress scenario. The lack of depreciation further underscores that the company's value lies entirely in its pipeline, which is subject to binary clinical outcomes.

The working capital adjustments are small relative to the operating loss, indicating that the company is not generating meaningful cash from changes in receivables, inventory, or payables. The positive swings in some quarters may reflect timing of payments to vendors or clinical trial sites, but they do not represent a sustainable source of liquidity. With no revenue, working capital management is unlikely to provide any buffer against the ongoing cash consumption.

The negligible buyback and absence of dividends confirm that the company is preserving every dollar for clinical development. The $66K buyback in Q2 2026 is immaterial and likely related to employee stock plans rather than a return of capital. The real capital deployment is the cash burn itself, which is effectively an investment in the pipeline, but the lack of external financing visibility raises concerns about future dilution.

The cumulative gap between net income and operating cash flow is driven by non-cash items such as stock-based compensation and warrant revaluations, which have inflated reported losses relative to actual cash outflows. However, the cash burn is still substantial and accelerating, with the last four quarters averaging -$15.4M per quarter. This divergence suggests that while the accounting losses are severe, the cash reality is slightly less dire, but the trend is clearly unsustainable without new capital.